Nutraceutix Inc. & Sinphar Co. to develop products for Asia
for the nutraceutical and pharmaceutical industries, has announced
the signing...
Nutraceutix, Inc., an American company providing patented products for the nutraceutical and pharmaceutical industries, has announced the signing of a memorandum of understanding with Sinphar Pharmaceutical Co., Ltd. a Taiwanese pharmaceutical group.
The two companies will co-develop dietary supplements, over the counter products and prescription drugs for Japan, China Philippines, Taiwan, Macao, Hong Kong, Korea, Singapore, Malaysia, and Indonesia.
Sinphar will co-develop Controlled Delivery Technology™ and probiotics products with Nutraceutix for the Taiwanese market.
Sinphar will also represent Nutraceutix technologies and products to its existing client base in Asian markets.
Sinphar will produce those technologies and products in Taiwan for export to its established territories.
Sinphar's Canadian subsidiary CanCap Pharmaceuticals of Richmond, B.C. will assume the responsibility of coordinating research activities developing products for the Asian market using Nutraceutix' patented technologies.
Nutraceutix Inc. possesses proven technologies and products for the nutraceutical industry.
In addition to patented ingredients like Calcium D-Glucarate™, Nutraceutix provides patented and proprietary technologies like Controlled Delivery Technology™, Molecular Dispersion Technology™, Self Emulsifying Technology™ and LiveBac® Probiotics.
Sinphar is a publicly traded company that develops, manufactures and commercialises pharmaceuticals, nutraceuticals and cosmetics products.
They have a line of Sinphar brand name products that are widely distributed throughout Taiwan and surrounding territories such as Macao, Hong Kong and Mainland China.
CanCap Pharmaceutical Ltd. is a subsidiary of Sinphar, located in Canada.
It is part of the Sinphar research and development centre and is responsible for development of new drug products and clinical trials.
Source: BridgeNews